Cadoo KA, Grisham RN, O'Cearbhaill RE, et al. - Researchers examined the safety and maximum tolerated dose (MTD) of olaparib with intravenous (IV)/intraperitoneal (IP) cisplatin/paclitaxel and IV bevacizumab, followed by olaparib and bevacizumab maintenance, in individuals with newly diagnosed ovarian cancer who had undergone primary debulking surgery. They treated 17 women (Cohort 1 [50 mg olaparib], 8 patients; Cohort 2 [100 mg], 3 patients; and Cohort 3 [200 mg], 6 patients). They found that the MTD of intermittently dosed olaparib with concurrent IV/IP cisplatin/paclitaxel and bevacizumab is 100 mg twice daily. They found low-grade non-hematologic toxicities. Dose reduction was required in one-third of individuals on olaparib maintenance.